Rita Nanda
Rita Nanda
Associate Professor, The University of Chicago
Verified email at medicine.bsd.uchicago.edu
Title
Cited by
Cited by
Year
The molecular portraits of breast tumors are conserved across microarray platforms
Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ...
BMC genomics 7 (1), 1-12, 2006
16322006
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma
CA Livasy, G Karaca, R Nanda, MS Tretiakova, OI Olopade, DT Moore, ...
Modern pathology 19 (2), 264-271, 2006
13512006
Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Journal of Clinical Oncology 34 (21), 2460, 2016
9192016
Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer
D Huo, F Ikpatt, A Khramtsov, JM Dangou, R Nanda, J Dignam, B Zhang, ...
Journal of Clinical Oncology 27 (27), 4515, 2009
4062009
Adaptive randomization of veliparib–carboplatin treatment in breast cancer
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
3802016
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies
DS Shames, L Girard, B Gao, M Sato, CM Lewis, N Shivapurkar, A Jiang, ...
PLoS Med 3 (12), e486, 2006
2792006
Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study
LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ...
JAMA oncology 5 (1), 74-82, 2019
2482019
Adaptive randomization of neratinib in early breast cancer
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
2382016
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Annals of Oncology 30 (3), 397-404, 2019
2372019
Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry
R Nanda, LP Schumm, S Cummings, JD Fackenthal, L Sveen, ...
Jama 294 (15), 1925-1933, 2005
2362005
Advances in breast cancer: pathways to personalized medicine
OI Olopade, TA Grushko, R Nanda, D Huo
Clinical Cancer Research 14 (24), 7988-7999, 2008
2252008
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 …
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ...
Journal of clinical oncology 31 (14), 1726, 2013
2182013
BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy
M Wei, TA Grushko, J Dignam, F Hagos, R Nanda, L Sveen, J Xu, ...
Cancer research 65 (23), 10692-10699, 2005
2032005
Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer
TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ...
Journal of clinical oncology 36 (9), 884, 2018
2022018
Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2.
R Nanda, MC Liu, C Yau, S Asare, N Hylton, LV Veer, J Perlmutter, ...
Journal of Clinical Oncology 35 (15_suppl), 506-506, 2017
2002017
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ...
Annals of Oncology 30 (3), 405-411, 2019
1792019
The role of tumor-associated macrophages in breast cancer progression
E Obeid, R Nanda, YX Fu, OI Olopade
International journal of oncology 43 (1), 5-12, 2013
1762013
Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).
TA Traina, K Miller, DA Yardley, J O'Shaughnessy, J Cortes, A Awada, ...
Journal of clinical oncology 33 (15_suppl), 1003-1003, 2015
1662015
Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer …
JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ...
Cancer 119 (10), 1776-1783, 2013
1612013
A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer
R Nanda, LQ Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
San Antonio Breast Cancer Symposium, 9-13, 2014
1502014
The system can't perform the operation now. Try again later.
Articles 1–20